COVID-19 vaccine effectiveness among immunocompromised populations: a targeted literature review of real-world studies

Fusco, Manuela Di; Lin, Jay; Vaghela, Shailja; Lingohr-Smith, Melissa; Nguyen, Jennifer; Sforzolini, Thomas Scassellati; Judy, Jennifer; Cané, Alejandro; Moran, Mary

doi:10.1101/2021.12.29.21268511

Cited by 1 publication

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This includes lack of long-term follow-up enabling a better understanding of waning which is critical when optimizing the timing of additional boosters in this high-risk population. Additionally, previous studies suggest lower effectiveness of the original monovalent Covid-19 vaccines among immunocompromised individuals relative to that observed in the general population (7,8).…”

Section: Introductionmentioning

confidence: 95%

Comparative effectiveness of bivalent BA.4.5 or BA.1 mRNA booster vaccines among immunocompromised individuals across three Nordic countries: a nationwide cohort study

Gram,

Thiesson,

Pihlström

et al. 2024

Preprint

View full text Add to dashboard Cite

Objectives To estimate the effectiveness and waning immunity of the bivalent BA.4-5 or BA.1 mRNA booster vaccine against Covid-19-related hospital admission and death in immunocompromised individuals. Design Nationwide cohort analyses using a matched cohort design. Setting Denmark, Finland, and Sweden, from 1 September 2022 to 31 October 2023. Participants All individuals aged 18 years or above with medical history of at least one immunocompromised condition, residency in Denmark, Finland or Sweden, no history of Covid-19-related hospitalization, and receipt of at least three Covid-19 vaccine doses as of study start, 1 September 2022. Individuals boosted with a BA.4-5 or BA.1 vaccine were matched 1:1 with unboosted individuals. Main outcome measures Country-combined vaccine effectiveness (VE) estimates against Covid-19 hospitalization and Covid-19-related death at day 270 of follow-up. Potential waning was assessed in 45-day intervals. Results A total of 352,762 BA.4-5 and 191,070 BA.1 booster vaccine doses were administered to immunocompromised individuals. At day 270, the comparative VE against Covid-19 hospitalization was 34.2% (95% CI, 7.1% to 61.3%) for the bivalent BA.4-5 vaccine (696 vs 1,128 events, risk difference [RD] per 100,000, -223.7, 95% CI, -411.5 to -36.0) and 42.6% (95% CI, 31.3% to 53.9%) for the BA.1 vaccine (395 vs 740 events, RD per 100,000, -385.0, -673.4 to -96.6) compared with matched unboosted. The comparative VE against Covid-19 death was 53.9% (95% CI, 38.6% to 69.3%) for the bivalent BA.4-5 vaccine (203 vs 457 events, RD per 100,000, -138.7, 95% CI, -195.5 to -81.9) and 57.9% (95% CI, 48.5% to 67.4%) for the BA.1 vaccine (112 vs 302 events, RD per 100,000, -220.6, -275.9 to -165.4). The VE estimates were highest in the first 45 days since eight days after vaccination (52.8% and 72.8% for bivalent BA.4-5 vaccine against Covid-19-related hospitalization and death, and 62.2% and 84.2% for bivalent BA.1 vaccine) and waned gradually during the 270 days of follow-up. Conclusions In immunocompromised individuals, vaccination with a bivalent BA.4-5 or BA.1 booster lowered the risk of Covid-19-related hospitalization and death over a follow-up period of 9 months. The effectiveness was highest during the first months since vaccination with subsequent gradual waning.

show abstract

Section: Introductionmentioning

confidence: 95%